MuSK MG clinical trials at UC Irvine

1 research study open to eligible people

Pharmacodynamics and Efficacy of CNP-106 in Subjects with Myasthenia Gravis
open to eligible people ages 18-75
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Orange, California and other locations

Last updated: February 12, 2025